4.1. CHARACTERIZATION OF FAMILIAL NON-BRCA1/2 BREAST TUMORS BY LOSS OF HETEROZYGOSIT Y AND IMMUNOPHENOT YPING

1 Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden 2 Dept. of Clinical Genetics, Erasmus Medical center, Rotterdam 3 Dept. of Human Genetics, University Medical Center Nijmegen 4 Netherlands Foundation for the Detection of Hereditary Tumors, Leiden 5 Dept. of Pathology, Leiden University Medical Center, Leiden 6 Dept. of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden

[1]  D. Easton,et al.  Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families , 2006 .

[2]  A. Lindblom,et al.  CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12. , 2005, International journal of molecular medicine.

[3]  A. Jauch,et al.  Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization , 2005, International journal of cancer.

[4]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[5]  Päivi Heikkilä,et al.  Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families , 2004, Breast Cancer Research.

[6]  Jian-Bing Fan,et al.  Tumorigenesis and Neoplastic Progression Quantitative Gene Expression Profiling in Formalin-Fixed , Paraffin-Embedded Tissues Using Universal Bead Arrays , 2004 .

[7]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[8]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[9]  David C Christiani,et al.  High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines , 2004, Oncogene.

[10]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[11]  P. Devilee,et al.  Extending the p16-Leiden tumour spectrum by respiratory tract tumours , 2004, Journal of Medical Genetics.

[12]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[13]  J. Klijn,et al.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.

[14]  D. Easton,et al.  EMGM Abstracts , 2003, Genetic epidemiology.

[15]  F. Wright,et al.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. , 2003, American journal of human genetics.

[16]  J. Cigudosa,et al.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. V. van't Veer,et al.  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. , 2003, Cancer research.

[19]  M. Ringnér,et al.  Molecular classification of familial non-BRCA1/BRCA2 breast cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Peto,et al.  The future of association studies of common cancers , 2003, Human Genetics.

[21]  G. Marth,et al.  STRP Screening Sets for the human genome at 5 cM density , 2003, BMC Genomics.

[22]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[24]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[25]  S. Seal,et al.  Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[27]  G. Abecasis,et al.  Merlin—rapid analysis of dense genetic maps using sparse gene flow trees , 2002, Nature Genetics.

[28]  P. Devilee,et al.  Ever since Knudson. , 2001, Trends in genetics : TIG.

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Weber,et al.  "Other" breast cancer susceptibility genes: searching for more holy grail. , 2001, Human molecular genetics.

[31]  C. Mathew,et al.  Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. , 2001, Cancer research.

[32]  G. Giles,et al.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. , 2001, American journal of human genetics.

[33]  S. Seal,et al.  Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 , 2000, Oncogene.

[34]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[35]  E. Gillanders,et al.  Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  D. Easton.  How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.

[38]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[39]  O. Kallioniemi,et al.  Somatic genetic alterations in BRCA2‐associated and sporadic male breast cancer , 1999, Genes, chromosomes & cancer.

[40]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[41]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[42]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[43]  L. Ala‐Kokko,et al.  Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[45]  J. Tischfield,et al.  Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. , 1997, American journal of human genetics.

[46]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[47]  J. Tischfield,et al.  High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. , 1997, Cancer research.

[48]  P. Schlag,et al.  Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families , 1997, Oncogene.

[49]  L Kruglyak,et al.  Parametric and nonparametric linkage analysis: a unified multipoint approach. , 1996, American journal of human genetics.

[50]  F R Rosendaal,et al.  Testing familial aggregation. , 1995, Biometrics.

[51]  J. Klijn,et al.  Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.

[52]  W. Zimmermann,et al.  Linkage analysis in German breast cancer families with early onset of the disease, using highly polymorphic markers from the chromosome 17q11-q24 region. , 1993, American journal of human genetics.

[53]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[54]  Joseph Haydn,et al.  Theme and variations , 1956 .

[55]  A. Templeton,et al.  Tumours of the Breast , 1894, The Hospital.